Inhibition of CYP3A by erythromycin: In vitro-in vivo correlation in rats

Xin Zhang, Raymond E. Galinsky, Robert E. Kimura, Sara Quinney, David R. Jones, Stephen D. Hall

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The prediction of in vivo drug-drug interactions from in vitro enzyme inhibition parameters remains challenging, particularly when time-dependent inhibition occurs. This study was designed to examine the accuracy of in vitro-derived parameters for the prediction of inhibition of CYP3A by erythromycin (ERY). Chronically cannulated rats were used to estimate the reduction in in vivo and in vitro intrinsic clearance (CLint) of midazolam (MDZ) after single and multiple doses of ERY; in vitro recovery of CLint was determined at 1, 2, 3, and 4 days after discontinuation of ERY. Enzyme inhibition parameters (kinact, KI, and K i) of ERY were estimated in vitro by using untreated rat liver microsomes. In vivo enzyme kinetic analysis indicated that single and multiple doses of ERY (150 mg/kg i.v. infusion over 4 h) reduced MDZ CLint by reversible and irreversible mechanisms, respectively. CYP3A inactivation after multiple doses of ERY treatment reflected metabolic intermediate complex formation without a significant change in hepatic CYP3A2 mRNA. A physiologically based pharmacokinetic model of the interaction between ERY and MDZ predicted a 2.6-fold decrease in CYP3A activity after repeated ERY treatment using in vitro-estimated enzyme inhibition parameters and in vivo degradation half-life of the enzyme (20 ± 6 h). The observed -fold decreases were 2.3-fold and 2.1-fold for the in vitro-estimated CYP3A activity and the in vivo CL int, respectively. This study demonstrates that in vivo DDIs are predictable from in vitro data when the appropriate model and parameter estimates are available.

Original languageEnglish
Pages (from-to)61-72
Number of pages12
JournalDrug Metabolism and Disposition
Volume38
Issue number1
DOIs
StatePublished - Jan 2010

Fingerprint

Cytochrome P-450 CYP3A
Erythromycin
Midazolam
Enzymes
In Vitro Techniques
Liver Microsomes
Drug Interactions
Half-Life
Pharmacokinetics
Messenger RNA
Liver

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Inhibition of CYP3A by erythromycin : In vitro-in vivo correlation in rats. / Zhang, Xin; Galinsky, Raymond E.; Kimura, Robert E.; Quinney, Sara; Jones, David R.; Hall, Stephen D.

In: Drug Metabolism and Disposition, Vol. 38, No. 1, 01.2010, p. 61-72.

Research output: Contribution to journalArticle

Zhang, Xin ; Galinsky, Raymond E. ; Kimura, Robert E. ; Quinney, Sara ; Jones, David R. ; Hall, Stephen D. / Inhibition of CYP3A by erythromycin : In vitro-in vivo correlation in rats. In: Drug Metabolism and Disposition. 2010 ; Vol. 38, No. 1. pp. 61-72.
@article{048b701831dd4209802821e6bd1e4980,
title = "Inhibition of CYP3A by erythromycin: In vitro-in vivo correlation in rats",
abstract = "The prediction of in vivo drug-drug interactions from in vitro enzyme inhibition parameters remains challenging, particularly when time-dependent inhibition occurs. This study was designed to examine the accuracy of in vitro-derived parameters for the prediction of inhibition of CYP3A by erythromycin (ERY). Chronically cannulated rats were used to estimate the reduction in in vivo and in vitro intrinsic clearance (CLint) of midazolam (MDZ) after single and multiple doses of ERY; in vitro recovery of CLint was determined at 1, 2, 3, and 4 days after discontinuation of ERY. Enzyme inhibition parameters (kinact, KI, and K i) of ERY were estimated in vitro by using untreated rat liver microsomes. In vivo enzyme kinetic analysis indicated that single and multiple doses of ERY (150 mg/kg i.v. infusion over 4 h) reduced MDZ CLint by reversible and irreversible mechanisms, respectively. CYP3A inactivation after multiple doses of ERY treatment reflected metabolic intermediate complex formation without a significant change in hepatic CYP3A2 mRNA. A physiologically based pharmacokinetic model of the interaction between ERY and MDZ predicted a 2.6-fold decrease in CYP3A activity after repeated ERY treatment using in vitro-estimated enzyme inhibition parameters and in vivo degradation half-life of the enzyme (20 ± 6 h). The observed -fold decreases were 2.3-fold and 2.1-fold for the in vitro-estimated CYP3A activity and the in vivo CL int, respectively. This study demonstrates that in vivo DDIs are predictable from in vitro data when the appropriate model and parameter estimates are available.",
author = "Xin Zhang and Galinsky, {Raymond E.} and Kimura, {Robert E.} and Sara Quinney and Jones, {David R.} and Hall, {Stephen D.}",
year = "2010",
month = "1",
doi = "10.1124/dmd.109.028290",
language = "English",
volume = "38",
pages = "61--72",
journal = "Drug Metabolism and Disposition",
issn = "0090-9556",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Inhibition of CYP3A by erythromycin

T2 - In vitro-in vivo correlation in rats

AU - Zhang, Xin

AU - Galinsky, Raymond E.

AU - Kimura, Robert E.

AU - Quinney, Sara

AU - Jones, David R.

AU - Hall, Stephen D.

PY - 2010/1

Y1 - 2010/1

N2 - The prediction of in vivo drug-drug interactions from in vitro enzyme inhibition parameters remains challenging, particularly when time-dependent inhibition occurs. This study was designed to examine the accuracy of in vitro-derived parameters for the prediction of inhibition of CYP3A by erythromycin (ERY). Chronically cannulated rats were used to estimate the reduction in in vivo and in vitro intrinsic clearance (CLint) of midazolam (MDZ) after single and multiple doses of ERY; in vitro recovery of CLint was determined at 1, 2, 3, and 4 days after discontinuation of ERY. Enzyme inhibition parameters (kinact, KI, and K i) of ERY were estimated in vitro by using untreated rat liver microsomes. In vivo enzyme kinetic analysis indicated that single and multiple doses of ERY (150 mg/kg i.v. infusion over 4 h) reduced MDZ CLint by reversible and irreversible mechanisms, respectively. CYP3A inactivation after multiple doses of ERY treatment reflected metabolic intermediate complex formation without a significant change in hepatic CYP3A2 mRNA. A physiologically based pharmacokinetic model of the interaction between ERY and MDZ predicted a 2.6-fold decrease in CYP3A activity after repeated ERY treatment using in vitro-estimated enzyme inhibition parameters and in vivo degradation half-life of the enzyme (20 ± 6 h). The observed -fold decreases were 2.3-fold and 2.1-fold for the in vitro-estimated CYP3A activity and the in vivo CL int, respectively. This study demonstrates that in vivo DDIs are predictable from in vitro data when the appropriate model and parameter estimates are available.

AB - The prediction of in vivo drug-drug interactions from in vitro enzyme inhibition parameters remains challenging, particularly when time-dependent inhibition occurs. This study was designed to examine the accuracy of in vitro-derived parameters for the prediction of inhibition of CYP3A by erythromycin (ERY). Chronically cannulated rats were used to estimate the reduction in in vivo and in vitro intrinsic clearance (CLint) of midazolam (MDZ) after single and multiple doses of ERY; in vitro recovery of CLint was determined at 1, 2, 3, and 4 days after discontinuation of ERY. Enzyme inhibition parameters (kinact, KI, and K i) of ERY were estimated in vitro by using untreated rat liver microsomes. In vivo enzyme kinetic analysis indicated that single and multiple doses of ERY (150 mg/kg i.v. infusion over 4 h) reduced MDZ CLint by reversible and irreversible mechanisms, respectively. CYP3A inactivation after multiple doses of ERY treatment reflected metabolic intermediate complex formation without a significant change in hepatic CYP3A2 mRNA. A physiologically based pharmacokinetic model of the interaction between ERY and MDZ predicted a 2.6-fold decrease in CYP3A activity after repeated ERY treatment using in vitro-estimated enzyme inhibition parameters and in vivo degradation half-life of the enzyme (20 ± 6 h). The observed -fold decreases were 2.3-fold and 2.1-fold for the in vitro-estimated CYP3A activity and the in vivo CL int, respectively. This study demonstrates that in vivo DDIs are predictable from in vitro data when the appropriate model and parameter estimates are available.

UR - http://www.scopus.com/inward/record.url?scp=73149102530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73149102530&partnerID=8YFLogxK

U2 - 10.1124/dmd.109.028290

DO - 10.1124/dmd.109.028290

M3 - Article

C2 - 19797607

AN - SCOPUS:73149102530

VL - 38

SP - 61

EP - 72

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

SN - 0090-9556

IS - 1

ER -